Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 7/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.40 |
| ▸ | JUN | P05412 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581284 | 0.98 | IDH1 (0.56) | IDH1HRH4MAPK8MAPK9CDK2 | |
| SCHEMBL4582376 | 0.84 | KDR (0.43) | IDH1CDK2MKNK1 | |
| SCHEMBL4581999 | 0.83 | HRH4 (0.56) | IDH1HRH4 | |
| SCHEMBL4581890 | 0.83 | IDH1 (0.54) | IDH1HRH4MKNK1MKNK2 | |
| SCHEMBL4581479 | 0.82 | IDH1 (0.44) | IDH1HRH4MKNK1MKNK2 | |
| SCHEMBL4580971 | 0.80 | IDH1 (0.40) | IDH1HRH4MKNK1MKNK2 | |
| SCHEMBL4580975 | 0.80 | IKBKB (0.41) | IDH1CDK2MKNK1 | |
| SCHEMBL4581501 | 0.80 | IDH1 (0.56) | IDH1 | |
| SCHEMBL4580841 | 0.80 | IDH1 (0.42) | IDH1HRH4MKNK1MKNK2 | |
| SCHEMBL4581855 | 0.80 | IDH1 (0.56) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | claimed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | claimed |
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | disclosed |
| EP-1448555-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | Celltech R & D Limited (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045941-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | ROR1, MAPK1, IRAK1 | IDH1 424/4885HRH4 52/4885MAPK8 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.